Longeveron/$LGVN
1D1W1MYTD1Y5YMAX
Capital at risk
About Longeveron
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
- Ticker
- $LGVN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 38
- Headquarters
- Miami, United States
- Website
- longeveron.com
Longeveron Metrics
BasicAdvanced
$7.9M
-
-$9.73
-0.25
-
Price and volume
Market cap
$7.9M
Beta
-0.25
52-week high
$12.30
52-week low
$2.30
Average daily volume
137K
Financial strength
Current ratio
2.629
Quick ratio
2.355
Total debt to equity
0.056
Profitability
EBITDA (TTM)
-22.44
Gross margin (TTM)
69.76%
Net profit margin (TTM)
-1,977.59%
Operating margin (TTM)
-1,975.99%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-90.95%
Return on equity (TTM)
-203.61%
Valuation
Price to revenue (TTM)
5.063
Price to book
0.76
Price to tangible book (TTM)
0.96
Price to free cash flow (TTM)
-0.291
Free cash flow yield (TTM)
-344.09%
Free cash flow per share (TTM)
-8.568
Growth
Revenue change (TTM)
-42.74%
Earnings per share change (TTM)
-23.78%
3-year revenue growth (CAGR)
10.41%
3-year earnings per share growth (CAGR)
-53.21%
Upcoming events
No upcoming events
Longeveron News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.